Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2023 16:01 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

NAARDEN, The Netherlands and MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
August 07, 2023 07:15 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights

-- Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe, which met the primary endpoint with 63.4% median reduction in LDL-C (p<0.0001) -- --...
June 09, 2023 16:01 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

NAARDEN, The Netherlands and MIAMI, June 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
June 06, 2023 23:25 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares

NAARDEN, The Netherlands and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
June 05, 2023 07:00 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients

-- Achieved Primary Endpoint with Statistically Significant 45.8% Median Reduction in LDL-C (p < 0.0001) in patients treated with 10mg obicetrapib-- -- 29.7% Median Reduction in Apo B and 37.0%...
June 03, 2023 12:15 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023

– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of <55...
May 31, 2023 08:00 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma to Present at Jefferies Healthcare Conference

NAARDEN, the Netherlands and MIAMI, May 31, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
May 23, 2023 08:00 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023

NAARDEN, the Netherlands and MIAMI, May 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the...
May 08, 2023 08:00 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights

-- Completed enrollment in BROOKLYN Phase 3 clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia (“HeFH”) ahead of schedule; topline results expected in 2H...
April 24, 2023 08:00 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

-- Enrollment Completed Several Months Ahead of Schedule, Reflecting Significant Unmet Need and Patient Demand for New Options ---- Topline Results Expected in 2H 2024 – NAARDEN, the Netherlands and...